A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.

Inclusion Criteria:

• Stage IV, non squamous NSCLC
• Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
• Have at least 1 measurable lesion per RECIST version 1.1

Exclusion Criteria:

• Have predominantly squamous cell histology NSCLC.
• Hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin